The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
ASP2215, a novel FLT3/AXL inhibitor: Preclinical evaluation in combination with cytarabine and anthracycline in acute myeloid leukemia (AML).
Yoko Ueno
Employment or Leadership Position - Astellas Pharma (B)
Naoki Kaneko
Employment or Leadership Position - Astellas Pharma
Rika Saito
Employment or Leadership Position - Astellas Pharma
Yutaka Kondoh
Employment or Leadership Position - Astellas Pharma
Itsuro Shimada
Employment or Leadership Position - Astellas Pharma
Masamichi Mori
Employment or Leadership Position - Astellas Pharma
Sadao Kuromitsu
Employment or Leadership Position - Astellas Pharma